Compare treatments
Compounded oral GLP-1 tablets vs compounded tirzepatide
A daily tablet against the weekly injection whose reference label carries a second approved use — set side by side, with a source on every clinical row.
This page is general information, not medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. A qualified clinician determines whether treatment is appropriate for you.
Generated from the family's dataset. No clinician has reviewed this page as a document.
What actually differs
This is the widest gap of the three pairings on this site: the two differ in what the molecule is, in how it is taken, in how often, and in what their reference labels are approved for. Nothing a reader learns about one side's schedule transfers to the other.
Each row below names the document it was read from, and the tablet column names which of the two molecules that document is actually about.
What this page does not tell you
It does not tell you which of the two to take. That is a clinical decision, and it depends on a medical history this page has never seen — which is also why there is no row below the table with a verdict in it.
It also does not report a head-to-head result, because neither reference label carries one against the other medicine named here. The two sets of trial results were measured in different groups of people, over different lengths of time, so reading the columns against each other as a contest reads something into them that the documents do not say.
Every cited row in the tablet column is read from the label of the only approved oral GLP-1 product, which is an oral semaglutide tablet. The tablet program here is a compounded preparation in a different form, and it also covers tirzepatide, for which no oral product is approved and no label exists. Nothing in this column describes what a prescription from this site arrives as. DailyMed, U.S. National Library of Medicine, 2026-08-19
Every cited row in the tirzepatide column is read from the label of Zepbound, an approved tirzepatide injection. What this site dispenses is a compounded preparation of the same molecule, which is not the product that label describes and was not the product its trials studied. DailyMed, U.S. National Library of Medicine, 2026-09-02
The Rybelsus label reports its results from trials in adults with type 2 diabetes, in trials of the approved oral semaglutide product running 26 weeks or longer. DailyMed, U.S. National Library of Medicine, 2026-08-19
The Zepbound label reports its results from trials in adults with obesity, or with overweight and at least one weight-related condition, treated for 72 weeks. DailyMed, U.S. National Library of Medicine, 2026-09-02
| Attribute | compounded oral GLP-1 tablets | compounded tirzepatide |
|---|---|---|
| How it is taken | The approved oral semaglutide label describes a tablet swallowed whole on an empty stomach, with no more than a small sip of plain water, at least 30 minutes before anything else is eaten or drunk. The compounded tablet dispensed here is a different preparation, and the directions that govern it come from the prescriber rather than from that label. DailyMed, U.S. National Library of Medicine, 2026-08-19 | An injection under the skin of the abdomen, thigh or upper arm. DailyMed, U.S. National Library of Medicine, 2026-09-02 |
| How often | The approved oral semaglutide label is a once-daily product, taken every day. No oral tirzepatide product is approved, so the tablet program's other molecule has no published oral schedule of its own. DailyMed, U.S. National Library of Medicine, 2026-08-19 | Once a week, on the same day each week. DailyMed, U.S. National Library of Medicine, 2026-09-02 |
| Published dose escalation | The approved oral semaglutide label starts at 3 mg once daily for 30 days, then moves to 7 mg once daily; after at least a further 30 days the dose may be increased to 14 mg once daily. Nothing equivalent is published for oral tirzepatide, because no oral tirzepatide product is approved. DailyMed, U.S. National Library of Medicine, 2026-08-19 | The label starts at 2.5 mg once weekly for four weeks, then 5 mg once weekly, with any further increase in 2.5 mg steps after at least four weeks; the maintenance doses are 5 mg, 10 mg and 15 mg. DailyMed, U.S. National Library of Medicine, 2026-09-02 |
| What the reference label reports for tolerability | The approved oral semaglutide label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation among the most common adverse reactions. DailyMed, U.S. National Library of Medicine, 2026-08-19 | The label lists nausea, diarrhea, vomiting, constipation, abdominal pain and injection-site reactions among the most common adverse reactions. DailyMed, U.S. National Library of Medicine, 2026-09-02 |
| What the reference label is approved for | The approved oral semaglutide product is approved as an addition to diet and exercise to improve blood-sugar control in adults with type 2 diabetes — not for weight management. DailyMed, U.S. National Library of Medicine, 2026-08-19 | The reference product is approved for long-term weight management alongside a reduced-calorie diet and increased physical activity, and separately for moderate to severe obstructive sleep apnea in adults with obesity. DailyMed, U.S. National Library of Medicine, 2026-09-02 |
| What it costs here | $129/moBilled monthly on a 6-month plan — for semaglutide — tirzepatide priced separately | $229/moBilled monthly on a 6-month plan |